HomeCompareNURO vs EPRT

NURO vs EPRT: Dividend Comparison 2026

NURO yields 43.67% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NURO wins by $219.2K in total portfolio value
10 years
NURO
NURO
● Live price
43.67%
Share price
$4.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$282.6K
Annual income
$51,335.69
Full NURO calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — NURO vs EPRT

📍 NURO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUROEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NURO + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NURO pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NURO
Annual income on $10K today (after 15% tax)
$3,711.79/yr
After 10yr DRIP, annual income (after tax)
$43,635.34/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, NURO beats the other by $32,720.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NURO + EPRT for your $10,000?

NURO: 50%EPRT: 50%
100% EPRT50/50100% NURO
Portfolio after 10yr
$173.0K
Annual income
$32,088.20/yr
Blended yield
18.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

NURO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NURO buys
0
EPRT buys
0
No recent congressional trades found for NURO or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUROEPRT
Forward yield43.67%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$282.6K$63.4K
Annual income after 10y$51,335.69$12,840.73
Total dividends collected$217.9K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: NURO vs EPRT ($10,000, DRIP)

YearNURO PortfolioNURO Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$15,067$4,366.81$11,205$505.18+$3.9KNURO
2$22,270$6,148.97$12,672$682.46+$9.6KNURO
3$32,324$8,494.27$14,490$930.48+$17.8KNURO
4$46,108$11,522.15$16,786$1,282.69+$29.3KNURO
5$64,697$15,360.67$19,753$1,791.56+$44.9KNURO
6$89,369$20,143.18$23,677$2,541.64+$65.7KNURO
7$121,629$26,004.42$29,008$3,672.99+$92.6KNURO
8$163,219$33,076.14$36,463$5,425.08+$126.8KNURO
9$216,127$41,482.53$47,238$8,221.57+$168.9KNURO
10$282,592$51,335.69$63,385$12,840.73+$219.2KNURO

NURO vs EPRT: Complete Analysis 2026

NUROStock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Full NURO Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this NURO vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NURO vs SCHDNURO vs JEPINURO vs ONURO vs KONURO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.